Skip to main content
SpringerLink
Log in

Optimal Management Strategies for Rhabdomyosarcoma in Children

  • Therapy In Practice
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Rhabdomyosarcoma is the most common sarcoma of childhood. Fortunately, the goal of cure is realistic for the majority of patients with localized tumors. However, management of these patients remains challenging. The fact that the tumor arises in a wide variety of primary sites, some of which are associated with specific patterns of local invasion, regional lymph node spread, and therapeutic response, requires physicians to be familiar with site-specific staging and treatment details. In addition, rhabdomyosarcoma requires multimodality therapy that can be associated with significant acute toxicities and long-term effects, particularly when administered to young children. These factors sometimes present a dilemma as to the best approach to optimize the chance of cure, minimize toxicity, and respect quality of life.

The purpose of this review is to discuss ‘optimal’ management of this complicated tumor. Since the tumor is relatively rare, requires highly specialized care, and important management questions remain to be answered, optimal management of rhabdomyosarcoma includes enrollment in clinical trials whenever possible. Appropriate management begins with establishing the correct pathologic diagnosis, histologic subtype, primary site, extent of disease (International Society of Pediatric Oncology [SIOP]-TNM-Union Internationale Contre le Cancer stage or Intergroup Rhabdomyosarcoma Study Group [IRSG] stage), and extent of resection (IRSG group). Cooperative groups throughout North America and Europe have defined risk-adapted treatment based on these factors; this treatment requires a coordinated management plan that includes surgery, chemotherapy, and usually radiotherapy.

The surgical approach for rhabdomyosarcoma is to excise the primary tumor whenever possible without causing major functional or cosmetic deficits. Wide excision is difficult in some primary sites and can be complicated by the fact that the tumor grows in a locally infiltrative manner so that complete resection is often neither possible nor medically indicated. Incompletely resected tumors are generally treated with radiotherapy. The cooperative groups reduce the dose of radiation based on the response of the tumor to chemotherapy and delayed primary resection to differing degrees. Response-adjusted radiation administration may reduce the long-term effects of radiotherapy, such as bone growth arrest, muscle atrophy, bladder dysfunction, and induction of second malignant neoplasms; however, it may also be associated with an increased risk of tumor recurrence.

All patients with rhabdomyosarcoma require chemotherapy. A backbone of vincristine and dactinomycin with either cyclophosphamide (VAC) or ifosfamide (IVA) has been established. Risk-adapted treatment involves reducing or eliminating the alklyating agent for patients with the most favorable disease characteristcs. Clinical trials are ongoing to improve outcomes for higher risk patients; newer agents, such as topotecan or irinotecan, in combination with VAC or use of agents in novel ways are being investigated. Acute and long-term toxicities associated with these chemotherapy regimens include myelosuppression, febrile neutropenia, hepatopathy, infertility, and second malignant neoplasms.

A 5-year survival rate >70% has been achieved in recent trials for patients with localized rhabdomyosarcoma. However, the outcome for patients who present with metastatic disease remains poor. In the future, risk-adapted classification of rhabdomyosarcoma will likely be based on biologic features, such as the presence of chromosomal translocations or specific gene expression profiles. It is hoped that newer therapies directed at specific molecular genetic defects will benefit all patients with rhabdomyosarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Ries LAG, Smith MA, Gurney JG, et al. Bethesda (MD): National Institutes of Health, 1999. Report no.: NIH-99-4649

  2. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I: a final report. Cancer 1988 Jan; 61(2): 209–20

    Article  PubMed  CAS  Google Scholar 

  3. Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993 Mar; 71(5): 1904–22

    Article  PubMed  CAS  Google Scholar 

  4. Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med 1969 Oct; 71(4): 747–52

    PubMed  CAS  Google Scholar 

  5. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990 Nov 30; 250(4985): 1233–8

    Article  PubMed  CAS  Google Scholar 

  6. Yang P, Grufferman S, Khoury MJ, et al. Association of childhood rhabdomyosarcoma with neurofibromatosis type I and birth defects. Genet Epidemiol 1995; 12(5): 467–74

    Article  PubMed  CAS  Google Scholar 

  7. Steenman M, Westerveld A, Mannens M. Genetics of Beckwith-Wiedemann syndrome-associated tumors: common genetic pathways. Genes Chromosomes Cancer 2000 May; 28(1): 1–13

    Article  PubMed  CAS  Google Scholar 

  8. Gripp KW. Tumor predisposition in Costello syndrome. Am J Med Genet 2005 Aug 15; 137(1): 72–7

    Article  Google Scholar 

  9. Ruymann FB, Maddux HR, Ragab A, et al. Congenital anomalies associated with rhabdomyosarcoma: an autopsy study of 115 cases. A report from the Inter-group Rhabdomyosarcoma Study Committee. Med Pediatr Oncol 1988; 16(1): 33–9

    Article  PubMed  CAS  Google Scholar 

  10. Morotti RA, Nicol KK, Parham DM, et al. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children’s Oncology Group experience. Am J Surg Pathol 2006; 30(8): 962–8

    Article  PubMed  Google Scholar 

  11. Willman JH, White K, Coffin CM. Pediatric core needle biopsy: strengths and limitations in evaluation of masses. Pediatr Dev Pathol 2001; 4(1): 46–52

    Article  PubMed  CAS  Google Scholar 

  12. Qualman SJ, Coffin CM, Newton WA, et al. Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr Dev Pathol 1998 Nov–Dec; 1(6): 550–61

    Article  PubMed  CAS  Google Scholar 

  13. Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003 Jan 1; 21(1): 78–84

    Article  PubMed  Google Scholar 

  14. Wiener ES, Anderson JR, Ojimba JI, et al. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? Semin Pediatr Surg 2001 Aug; 10(3): 146–52

    Article  PubMed  CAS  Google Scholar 

  15. Neville HL, Andrassy RJ, Lobe TE, et al. Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997). J Pediatr Surg 2000 Feb; 35(2): 317–21

    Article  PubMed  CAS  Google Scholar 

  16. Neville HL, Andrassy RJ, Lally KP, et al. Lymphatic mapping with sentinel node biopsy in pediatric patients. J Pediatr Surg 2000 Jun; 35(6): 961–4

    Article  PubMed  CAS  Google Scholar 

  17. Michalski JM, Meza J, Breneman JC, et al. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. Int J Radiat Oncol Biol Phys 2004 Jul 15; 59(4): 1027–38

    Article  PubMed  Google Scholar 

  18. Rodary C, Flamant F, Donaldson SS. An attempt to use a common staging system in rhabdomyosarcoma: a report of an international workshop initiated by the International Society of Pediatric Oncology (SIOP). Med Pediatr Oncol 1989; 17(3): 210–5

    Article  PubMed  CAS  Google Scholar 

  19. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001 Jun 15; 19(12): 3091–102

    PubMed  CAS  Google Scholar 

  20. Spunt SL, Lobe TE, Pappo AS, Aggressive surgery is unwarranted for biliary tract rhabdomyosarcoma. J Pediatr Surg 2000 Feb; 35(2): 309–16

    Article  PubMed  CAS  Google Scholar 

  21. Koscielniak E, Harms D, Henze G, et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 1999 Dec; 17(12): 3706–19

    PubMed  CAS  Google Scholar 

  22. Stevens MC, Rey A, Bouvet N, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology: SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 2005 Apr 20; 23(12): 2618–28

    Article  PubMed  Google Scholar 

  23. Meza JL, Anderson J, Pappo AS, et al. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children’s Oncology Group. J Clin Oncol 2006 Aug; 24(24): 3844–51

    Article  PubMed  Google Scholar 

  24. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995 Mar; 13(3): 610–30

    PubMed  CAS  Google Scholar 

  25. Donaldson SS, Anderson JR. Rhabdomyosarcoma: many similarities, a few philosophical differences. J Clin Oncol 2005 Apr 20; 23(12): 2586–7

    Article  PubMed  Google Scholar 

  26. Hawkins DS, Stoner J, Kao S, et al. Prognostic significance of residual mass at the end of therapy in Group III rhabdomyosaroma (RMS): Intergroup Rhabdomyosarcoma Study (IRS)-IV experience. J Clin Oncol (Supplement) 2005 Jun 1; 23(16S): 8501

    Google Scholar 

  27. Arndt CA, Hammond S, Rodeberg D, et al. Significance of persistent mature rhabdomyoblasts in bladder/prostate rhabdomyosarcoma: results from IRS IV. J Pediatr Hematol Oncol 2006 Sep; 28(9): 563–7

    Article  PubMed  Google Scholar 

  28. Arndt CA, Donaldson SS, Anderson JR, et al. What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract? Cancer 2001 Jun 15; 91(12): 2454–68

    Article  PubMed  CAS  Google Scholar 

  29. Wolden SL, Wexler LH, Kraus DH, et al. Intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2005; 61(5): 1432–8

    Article  PubMed  Google Scholar 

  30. Merchant TE, Parsh N, Lezamo El Valle P, et al. Brachytherapy for pediatric soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 2000; 46(2): 427–32

    Article  PubMed  CAS  Google Scholar 

  31. Timmerman B, Schuck A, Niggli F, et al. Spot-scanning proton therapy for malignant soft tissue tumors in childhood: first experiences at the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys 2007; 67(2): 497–594

    Article  Google Scholar 

  32. Donaldson SS, Meza J, Breneman JC, et al. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma: a report from the IRSG. Int J Radiat Oncol Biol Phys 2001 Nov 1; 51(3): 718–28

    Article  PubMed  CAS  Google Scholar 

  33. Puri DR, Wexler LH, Meyers PA, et al. The challenging role of radiation therapy for very young children with rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2006; 65(4): 117–84

    Article  Google Scholar 

  34. Arndt C, Hawkins D, Anderson JR, et al. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J Clin Oncol 2004 May 15; 22(10): 1894–901

    Article  PubMed  CAS  Google Scholar 

  35. Sandler E, Lyden E, Ruymann F, et al. Efficacy of ifosfamide and doxorubicin given as a phase II “window” in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. Med Pediatr Oncol 2001 Nov; 37(5): 442–8

    Article  PubMed  CAS  Google Scholar 

  36. Pappo AS, Lyden E, Breneman J, et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. J Clin Oncol 2001 Jan 1; 19(1): 213–9

    PubMed  CAS  Google Scholar 

  37. Walterhouse DO, Lyden ER, Breitfeld PP, et al. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children’s Oncology Group study. J Clin Oncol 2004 Apr 15; 22(8): 1398–403

    Article  PubMed  CAS  Google Scholar 

  38. Lager JJ, Lyden ER, Anderson JR, et al. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol 2006 Jul 20; 24(21): 3415–22

    Article  PubMed  Google Scholar 

  39. Oberlin O, Rey A, Anderson J, et al. Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment: results of an international workshop. J Clin Oncol 2001 Jan 1; 19(1): 197–204

    PubMed  CAS  Google Scholar 

  40. Ferrari A, Bisogno G, Casanova M, et al. Is alveolar histotype a prognostic factor in paratesticular rhabdomyosarcoma? The experience of Italian and German Soft Tissue Sarcoma Cooperative Group. Pediatr Blood Cancer 2004 Feb; 42(2): 134–8

    Article  PubMed  Google Scholar 

  41. Bisogno G, Ferrari A, Bergeron C, et al. The IVADo regimen: a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma. A pilot study on the behalf of the European pediatric Soft tissue sarcoma Study Group. Cancer 2005 Apr; 103(8): 1719–24

    Article  PubMed  CAS  Google Scholar 

  42. Casanova M, Ferrari A, Bisogno G, et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 2004 Oct; 101(7): 1664–71

    Article  PubMed  CAS  Google Scholar 

  43. Womer RB, Daller RT, Fenton JG, et al. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing’s sarcomas and soft tissue sarcomas in children. Eur J Cancer 2000 Jan; 36(1): 87–94

    Article  PubMed  CAS  Google Scholar 

  44. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007; 49(9): 928–40

    Article  PubMed  Google Scholar 

  45. Presta LG, Chen H, O’Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997 Oct; 57(20): 4593–9

    PubMed  CAS  Google Scholar 

  46. Gee MF, Tsuchida R, Eichler-Jonsson C, et al. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene 2005 Dec; 24(54): 8025–37

    Article  PubMed  CAS  Google Scholar 

  47. Rad FH, Le Buanec H, Paturance S, et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A 2007 Feb; 104(8): 2837–42

    Article  PubMed  CAS  Google Scholar 

  48. Maris JM, Courtright J, Houghton PJ, et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer. Epub 2007 Apr

    Google Scholar 

  49. Hosoi H, Dilling MB, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999 Feb; 59(4): 886–94

    PubMed  CAS  Google Scholar 

  50. Wan X, Shen N, Mendoza A, et al. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 2006 May; 8(5): 394–401

    Article  PubMed  CAS  Google Scholar 

  51. Koscielniak E, Klingebiel TH, Peters C, et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 1997 Feb; 19(3): 227–31

    Article  PubMed  CAS  Google Scholar 

  52. Boulad F, Kernan NA, LaQuaglia MP, et al. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing’s sarcoma, and undifferentiated sarcoma. J Clin Oncol 1998 May; 16(5): 1697–706

    PubMed  CAS  Google Scholar 

  53. Walterhouse DO, Hoover ML, Marymont MA, et al. High-dose chemotherapy followed by peripheral blood stem cell rescue for metastatic rhabdomyosarcoma: the experience at Chicago Children’s Memorial Hospital. Med Pediatr Oncol 1999 Feb; 32(2): 88–92

    Article  PubMed  CAS  Google Scholar 

  54. Carli M, Colombatti R, Oberlin O, et al. High-dose melphalan with autologous stem cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 1999 Sep; 17(9): 2796–803

    PubMed  CAS  Google Scholar 

  55. Kenney LB, Laufer MR, Grant FD, et al. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer 2001 Feb 1; 91(3): 613–21

    Article  PubMed  CAS  Google Scholar 

  56. Spunt SL, Sweeney TA, Hudson MM, et al. Late effects of pelvic rhabdomyosarcoma and its treatment in female survivors. J Clin Oncol 2005 Oct; 23(28): 7143–51

    Article  PubMed  Google Scholar 

  57. Sung L, Anderson JR, Donaldson SS, et al. Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Eur J Cancer 2004 Aug; 40(12): 1878–85

    Article  PubMed  Google Scholar 

  58. Raney B, Anderson J, Jenney M, et al. Late effects in 164 patients with rhabdomyosarcoma of the bladder/prostate region: a report from the international workshop. J Urol 2006 Nov; 176(5): 2190–4

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Dr Walterhouse is a member of the Soft Tissue Sarcoma Committee of the Children’s Oncology Group (STS COG) and study chair for COG ARST0331. No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Children’s Memorial Hospital, Northwestern University Feinberg School of Medicine, 2300 Children’s Plaza, Box 30, Chicago, Illinois, 60614, USA

    David Walterhouse & Andrea Watson

Authors
  1. David Walterhouse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Watson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Walterhouse.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walterhouse, D., Watson, A. Optimal Management Strategies for Rhabdomyosarcoma in Children. Pediatr Drugs 9, 391–400 (2007). https://doi.org/10.2165/00148581-200709060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00148581-200709060-00006

Keywords

Search

Navigation